胃癌患者血清CXCL12、TPS、sFas的表达和临床意义

The clinical significance of serum CXCL12,TPS and sFas in patients with gastric cancer

目的研究胃癌患者血清中趋化因子CXCL12、组织多肽特异性抗原(TPS)和可溶性凋亡相关因子(sFas)的水平变化,探讨其临床诊断价值。方法根据胃镜和组织病理学检查结果将83例受检者分为3组:1胃癌组39例;2非胃部的肿瘤患者组24例;3慢性非萎缩胃炎组20例。用ELISA方法定量测定3组患者血清CXCL12、TPS和sFas的水平。结果与慢性非萎缩胃炎组相比,胃癌组的CXCL12和sFas显著升高(P<0.01),TPS水平无统计学差异(P>0.05)。胃癌组与其他肿瘤组的CXCL12、TPS、aFas水平均无统计学差异(P>0.05)。与胃癌Ⅰ、Ⅱ期组比较,胃癌Ⅲ、Ⅳ期组血清sFas水平显著升高(P<0.01),CXCL12和TPS水平比较无统计学差异(P>0.05)。结论 CXCL12、sFas的异常变化与胃癌的发生发展有密切关系,可能参与了胃癌的免疫逃逸机制。

Objective To discuss the meaning of clinical diagnosis through studying the changes in serum levels of CXCL12,TPS and sFas in patients with gastric cancer. Methods The serum levels of CXCL12,TPS and sFas in 83 patients were tested by ELISA for quantitative determination. These cases were divided into three groups according to the results of gastroscopy and histopathological examination of biopsies.There were 39 patients with gastric cancer in group 1,24 cases with cancer at other parts of body besides stomach were allocated in group 2,and20 patients with chronic non-atrophic gastritis were allocated in group 3（ control group）. Results In comparison with group 3,the serum levels of of CXCL12（ P〈0. 05） and sFas（ P〈0. 01） were increased in group 1,and there was no statistical difference in serum level of TPS between group 1 and group 3. In comparison with 1st stage and 2nd stage gastric cancer,levels of serum sFas,TPS and CXCL12 were significantly higher in patients with 3rd stage and 4th stage gastric cancer（ P〈0. 01）,there was no significant difference in outcome between serum level of CXCL12 and serum level of TPS（ P〉0. 05）. Conclusion The changes in serum levels of CXCL12 and sFas were closely related with the development and progress of gastric cancer,they may be involved in the immune escape mechanism of gastric cancer. The serum level of sFas is associated with the degree of tumor differentiation,the higher its value,then the worst will be the prognosis.